Download VIEW PDF - Practical Dermatology

Therapeutics Update
Product News
Gaining Clarity. Patients with acne may be pleased
to know that a brand-new OTC agent has recently
become available. Stiefel, a GSK company’s, new acne
regimen, The MaxClarity regimen, is now widely
available. MaxClarity uses VersaFoam Technology to
enhance penetration of benzoyl peroxide and salicyclic
acid. New clinical data indicated that two thirds of
patients experienced significant improvement in acne
with one week of use of MaxClarity, while 80 percent
of users experienced clinically significant improvements at four weeks, according to Stiefel/GSK. The
system includes a Deep Cleanser, Advanced Acne
Treatment, and Rejuvenating Toner. Purchases can
also be made online at www.maxclarity.com.
Before Zeltiq
CoolSculpting Coming to
Practices. A novel, non-invasive
fat reduction device, Zeltiq has
earned FDA clearance for treatment of the flank areas of the
torso. Based on the science of
After Zeltiq
Cryolipolysis or cold lipolysis,
Zeltiq’s unique CoolSculpting
technique involves use of
advanced cooling to gently and
effectively reduce fat bulges in
targeted areas of the body without needles, incisions,
pain medication, or recovery time. Fat cells are naturally more sensitive to the effects of cold than other
cells, the developer explains, permitting the device to
target and kill only the underlying fat, leaving surface
skin tissue unaffected. Among patients treated at 12
centers nationwide, there was an average fat layer
reduction of 20 percent at four months after only one
procedure.
Restoring Balance. The latest product in the Cetaphil
line is designed specifically to manage symptoms of
eczema. Cetaphil Restoraderm Skin Restoring Body
Wash and Skin Restoring Moisturizer soothe itch by
enhancing the skin’s ability to restore hydration and
repair the epidermal barrier. The Skin Restoring
Moisturizer contains a combination of filaggrin break-
down product and ceramides, while the Skin
Restoring Body Wash rebuilds the lipid bilayer during
bathing, allowing for maximum replenishment of
moisture, Galderma says.
Cosmetics For a Cause. For the launch of their new
pink Radiance Bx Finishing Lines + DMAE (dimethylaminoethanol) anti-aging treatment in October 2010,
Mesoestetic will donate 10 percent of proceeds from
the month’s sales of the product to breast cancer
research. DMAE is an anti-flaccidity agent that penetrates deep into the dermis to strengthen the connective tissue and stretch the skin’s surface, producing an
immediate lifting effect, Mesoestetic says. Other ingredients include Acetyl Hexapeptide-3, Palmitoyl
Pentapeptide-3, Palmitoyl Tripeptide-3, Ascorbyl
Glucoside and common oat seed extract, which work
collectively to stimulate collagen and enhance skin
elasticity and firmness.
Peel in a Jar? With an effective pH of 2.1 to
2.3, Lexli daily exfoliant differs from
other OTC products because it
contains an effective pH near
that of a chemical peel,
according to developer
AloeGlyC. They say
the product's base
contains pharmaceutical-grade aloe to counteract the potential for inflammation from glycolic acid and antioxidants and vitamins C, A and E to protect the skin from environmental damage. AloeGlyC products are available to skincare professionals.
Home Laser. Palomar Medical Technologies Inc.
recently announced that it would move the launch of
its patented, home-use laser for the treatment of periorbital wrinkles to the Spring of 2011. The device is
the only laser with over-the-counter clearance from
the FDA for the treatment of periorbital wrinkles.
OTC clearance allows the laser to be marketed and
sold directly to consumers without a prescription.
October 2010 |
Practical Dermatology | 47
Therapeutics Update
Product News
Targeting Psoriasis at Home. Personal Targeted
Phototherapy for psoriasis is now available from
Levia, an at-home (or in-office) therapeutic device
from Lerner Medical Devices. Levia, a new class of
UVB medical device, is a safe and effective non-drug
option for the self-treatment of scalp and small area
psoriasis. It incorporates two proprietary beam delivery attachments, the LiteBrush and LiteSpot, which
ensure precise and safe delivery of therapeutic UV
light. For more information, visit www.mylevia.com.
Opal Updated.
An update to a
15-year-old fade
gel, the new
Black Opal Fade
Systems are
intended to treat Patient treated with Black Opal Fade System
hyperpigmentation and reactive skin. The highest
concentration of hydroquinone available OTC is
combined with Citrus and Lotus Extracts in the BioIntensive Skin Complex to even tone and provide
skin brightness. The new Black Opal Fade Collection
includes Advanced Dual Complex Fade Gel
Maximum Strength or Sensitive Skin Formula, Body
Fade Crème Maximum Strength or Sensitive Skin
Formula, and Daily Fade Creme SPF 15 Maximum
Strength or Sensitive Skin Formula. Products retail
for $12.95 to $15.95. ■
Advertising Index October 2010
Advertiser. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Page
Allergan,Inc.
www.allergan.com/site/skin
Aczone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51-52
Astellas Pharma
www.astellas.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23
Coria Laboratories
www.corialabs.com
Atralin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19-20
Refissa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7-8
FDAACTIONS
Cosmetic Surgery Forum
www.cosmeticsurgeryforum.com/ . . . . . . . . . . . . . . . . . .49
Ipilimumab Accepted for Review. FDA recently accepted for filing
and review the Biologics License Application for ipilimumab
(Bristol-Myers Squibb) for the treatment of adult patients with
advanced melanoma who have been previously treated.
Ipilimumab is a novel T-cell potentiator that specifically blocks
the inhibitory signal of CTLA-4, a molecule that plays a critical
role in regulating natural immune responses. The filing is based
on results from the primary analysis of the pivotal MDX010-020
trial, which were published online in the New England Journal of
Medicine and presented at the American Society of Clinical
Oncology in June. The study compared the overall survival rate of
patients who received ipilimumab plus the gp100 vaccine (3
mg/kg and 1 mg/kg every three weeks for four doses), ipilimumab alone (3 mg/kg every three weeks for four doses), and
the control therapy of gp100 alone. Based on the FDA’s sixmonth goal for completing priority reviews, the projected FDA
action date is December 25, 2010.
Galderma
www.galdermausa.com
Psoriasis Pro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42
48 | Practical Dermatology
| October 2010
Ortho Dermatologics
www.orthodermatologics.com
Retin-A Micro . . . . . . . . . . . . . . . . . . . . . . . . . .2-3, 33
Stiefel a GSK Company
www.stiefel.com
Altabax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27-28
Duac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11-12
Winter Clinical Dermatology Conference
www.clinicaldermconf.org/ . . . . . . . . . . . . . . . . . . . . . . .41
For advertising inquiries please contact :
Alan Guralnick, Group Publisher
[email protected] • 484-581-1832
Ali Kinnie, Publisher
[email protected] • 917-589-4160